Avsnitt
-
Send us a text
Pedro Sanchez de Lozada is Co-Founder and CEO of Canid ( https://www.canid.io/ ), a company which is modernizing every aspect of providing vaccines in pediatrics, from operations, to finances, to maximizing care. Canid focuses the details of executing a vaccine program so that pediatricians can instead focus on the children.
Pedro is a seasoned CEO with a background in early-stage startup development, operations, and marketing at prominent venture-backed companies, including roles as: Director Of Marketing at Merlin, Head of Launch in Washington DC at Rinse, Growth Engineer at Koding, Business Development and Marketing professional at Udemy, and Vice-president of Marketing at Road to Innovative Social Entrepreneurship.
Pedro has also served as a Curator at TEDxUChicago, Founder of LogiMD, and was a Fellow at On Deck.
Pedro has a Bachelor of Arts in Economics from the University of Chicago.
#PedroSanchezDeLozada #Canid #Vaccines #Vaccination #Pediatrics #VaccineAcquisitionCosts #ReimbursementRates #Overhead #InventoryManagement #ImmunizationInformationSystems #StateImmunizationRegistries #AdvisoryCommitteeOnImmunizationPractices #ACIP #PatientEligibility #Procurement #Pediatricians #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
-
Send us a text
Dr. Marc Salzberg, MD is President, Chief Executive Officer & Chief Medical Officer of Airway Therapeutics ( https://www.airwaytherapeutics.com/ ), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases.
Dr. Salzberg has more than 25 years of academic and pharmaceutical experience in the management of drug development and clinical research, including medical management of anti-viral drugs clinical development and market introduction including saquinavir and ganciclovir. He spent several years at Roche’s headquarters in Basel, Switzerland as well as its affiliate in Toronto, Canada. As Head of Clinical Cancer Research at the Basel University, he co-founded and managed a clinical research network in Switzerland (CCRC).
During his career, Dr. Salzberg has successfully managed the growth and acquisition of two contract research organizations benefitting shareholders. He was a founder and President of Pharma Brains, a European boutique CRO, which has been acquired by Medpace, a US based global CRO, after 10 years of successful growth under his leadership. He then served as Vice President of Medical Affairs at Medpace.
Dr. Salzberg earned his Medical Doctorate degree from the University of Basel, Switzerland. His medical training and practice include pediatrics/ neonatology and oncology.
#MarcSalzberg #AirwayTherapeutics #HumanSurfactantProteinD #Collectin #PathogenRecognition #RespiratoryDiseases #InflammatoryResponse #BronchopulmonaryDysplasia #ZelpultideAlfa #Covid #Asthma #COPD #Influenza #RSV #ARDS #AcuteRespiratoryDistressSyndrome #ChronicObstructivePulmonaryDisease #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
-
Send us a text
Paul Keable is Chief Strategy Officer at Ashley Madison ( https://www.ashleymadison.com/ ) - the global online dating and social networking platform, specifically catering to individuals in committed relationships seeking discreet connections.
As Chief Strategy Officer, Paul oversees the strategic direction of Ashley Madison, emphasizing discretion, authenticity, and innovation within the dating industry. Under his leadership, the platform has implemented initiatives such as user verification through government IDs to combat fraudulent activity and build trust among members.
Paul has become a prominent figure at the intersection of technology, culture, and societal norms, offering insights on shifting dynamics in relationships and online dating.
Prior to Ashley Madison, Paul spent the past two decades in communications, public relations and branding, at agencies including Ketchum and MSL, working with a lot of tier-one brands across both the technology and consumer goods sectors.
Paul studied Corporate Communications at Centennial College and English at York University.
Important Episode Links -
Decoding Gen Z: A global report on non-monogamy, sex, and the desire for discretion -
https://www.ashley.date/wp-content/uploads/Gen-Z-Report-USA.pdf
YouGov Survey: Relationships, April 2025 -
https://ygo-assets-websites-editorial-emea.yougov.net/documents/Relationships_poll_results.pdf
#PaulKeable #AshleyMadison #OnlineDating #CommittedRelationships #DiscreetConnections #SocietalNorms #DatingTrends #RelationshipNorms #MarriedDating #Discretion #Privacy #Authenticity #Trust #Culture #Polyamorous #Monogamy #MatchingAlgorithms #DigitalIntimacy #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
-
Send us a text
William Ho is a Co-Founder, and has served as the President, Chief Executive Officer, and Director of IN8bio ( https://in8bio.com/ ), a biotech company with a mission of developing next-generation therapies for treating cancer, with a focus on gamma-delta T cells, since its inception.
Mr. Ho has worked in the biotechnology industry for nearly 24 years.
Prior to the founding of IN8bio, from 2014 to 2017, Mr. Ho was the Founder and Managing Partner at AlephPoint Capital, a private healthcare investment fund. Prior to that, Mr. Ho was at New Leaf Venture Partners, a leading healthcare venture capital firm, where he launched and managed the public investments and cross-over portfolio and served as its Public Investment Director from 2010 to 2014.
Previously, Mr. Ho served as a Senior Equity Research Analyst at Bank of America from 2006 to 2009 and an Equity Research Analyst at Piper Jaffray & Co. from 2003 to 2006, covering the biotechnology and life-science tools sectors.
Earlier in his career, Mr. Ho was responsible for FP&A and operational analysis at CuraGen Corporation and worked as an Associate on the Healthcare Investment Banking team at Cowen, Inc.
Mr. Ho was an inductee into the McMaster University Alumni Gallery in 2020 and previously served as a member of their Dean’s Advisory Board for the Faculty of Science.
Mr. Ho received an MBA from the University of Notre Dame and a B.S. in Biochemistry from McMaster University.
#WilliamHo #IN8bio #GammaDeltaTCells #ImmuneSystem #Glioblastoma #AcuteMyeloidLeukemia #NonSignalingCART #InducedPluripotentStemCells
#Oncology #Immunooncology #Cancer #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
-
Send us a text
Dr. Thomas Ehmer, Ph.D. ( https://www.linkedin.com/in/tehmer/ ) is a seasoned technology strategist with over two decades of experience in IT innovation, business development, and R&D within the pharmaceutical industry, and co-founder of the Quantum Interest Group, at Merck KGaA Darmstadt, Germany ( https://www.emdgroup.com/en ).
Dr. Ehmer currently is in the Sector Data Office - AI Governance and Innovation Incubator at Merck KGaA Darmstadt, Germany, where he scouts emerging and disruptive technologies, demonstrating their potential value for R&D applications, with a focus on quantum technologies.
Throughout his career at Merck KGaA Darmstadt, Germany, Dr. Ehmer has played a pivotal role in shaping IT strategy, business process optimization, and digital transformation across the entire pharmaceutical value chain, currently focusing on transparent AI and how and where emerging technology can help patients live a better life. His expertise spans technology scouting, business analysis, and IT program leadership, having successfully driven major global projects.
Beyond his corporate career, Dr. Ehmer is an active private seed investor and has contributed to quantum computing research and applications in drug discovery, authoring publications on the potential of quantum computing and machine learning in pharmaceutical R&D ( https://onlinelibrary.wiley.com/doi/10.1002/9783527840748.ch26 ).
Dr. Ehmer holds a Ph.D. in Physics, Biophysics, and Physiology from Heidelberg University and continues to mentor within the German Physical Society / Deutsche Physikalische Gesellschaft (DPG). His forward-thinking approach, combined with deep technical expertise, has earned him multiple innovation awards, and he remains dedicated to bridging the gap between emerging technologies and real-world industry applications.
Important Episode Link - Entangled Health Podcast -
https://podcasts.apple.com/us/podcast/entangled-health/id1819364423
#ThomasEhmer #MerckKGaADarmstadt #Physics #Biophysics #Physiology #GermanPhysicalSociety #QuantumComputing #QuantumSensing #MolecularImaging #Spectroscopy #DrugScreening #Diagnostics #QuantumSensors #QuantumMagnetometers #QuantumGravimeters #Biomanufacturing #QualityControl #Neuroscience #BrainDrugInterface #ReservoirComputing #QuantumMachineLearning #Bioconvergence #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
-
Send us a text
Josh Haimson is Co-Founder and CEO of Inductive Bio ( https://www.inductive.bio/about ), a technology company focused on democratizing artificial intelligence (AI) models to transform small molecule drug discovery, eliminating Absorption, Distribution, Metabolism, Excretion and Toxicology (ADMET) bottlenecks with state-of-the-art AI models and generative chemistry, powered by a unique pre-competitive data consortium.
Josh has spent his career focused on the intersection of machine learning, product, and life sciences/healthcare.
Prior to Inductive, Josh was the Director of Product for the ML and data curation organizations at Flatiron Health, where his teams worked to generate real-world evidence (RWE) at scale across Flatiron’s network of over 2 million active cancer patients for use by researchers in pharma, academia, and government.
Prior to Flatiron, Josh was at MIT studying computer science and working with researchers at Massachusetts General Hospital to use ML and NLP to predict patient response to cardiac resynchronization therapy.
#JoshHaimson #InductiveBio #SmallMolecule #DrugDiscovery #Absorption #Distribution #Metabolism #Excretion #Toxicology #ADMET #AI #GenerativeChemistry #MachineLearning #CardiacResynchronizationTherapy #MolecularGlue #FlatironHealth #PreCompetitiveDataConsortium #RealWorldEvidence #RealWorldData #RWE #ArtificialIntelligence #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
-
Send us a text
Dr. Shai Melcer, Ph.D. is Head of the National Bioconvergence Program ( https://bioconvergence.org.il/ ) at the Israel Innovation Authority ( https://innovationisrael.org.il/en/ ).
In this role, Dr. Melcer, who brings 15 years of experience and entrepreneurship in the bio-medical ecosystem, leads the implementation of the bioconvergence goals for TELEM – the National Infrastructure Forum for Research and Development ( https://innovationisrael.org.il/en/programs/telem-the-national-infrastructure-forum-for-research-and-development/ ).
Dr. Melcer has both an LLM in Law and Ph.D. in genetics from the Hebrew University, and has collaborated with various entities such as the Hebrew University, Hadassah Medical Center, IBM, the Jerusalem Development Authority (Bio-Jerusalem), and others to establish numerous innovative bio-med ventures, including BioGiv, BIOHOUSE, and Hadassah Accelerator.
In his public and private sector activities, Dr. Melcer has worked with hundreds of biomedical companies in Israel and around the world in the fields of pharma-biotech, medical devices, and digital health, many of which are in the bioconvergence sector. He also served as the Chief Business Officer at Minovia, a company in the liquid biopsy consortium established by the Israel Innovation Authority as part of the bio-convergence program.
#Bioconvergence #IsraelInnovationAuthority #ShaiMelcer #BugEra #Biotic #ClimateTech #Biomanufacturing #Biofuel #Biodiesel #SustainableAviationFuel #BlackSoldierFly #BiodegradablePolymers #BioBased #Microplastics #CarbonFootprint #Renewable #Sustainable #TechnologicalIncubators #InnovationCenters #AngelInvestors #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #ResearchSupport the show
-
Send us a text
Dr. Robert Schwab, MD is a Resident Physician, Research Specialist, and Hematology-Oncology Fellow at Penn Medicine, University of Pennsylvania Health System ( https://www3.pennmedicine.org/departments-and-centers/department-of-medicine/divisions/hematology-and-oncology/education-and-training/hematology-oncology-fellowship/fellows ).
Dr. Schwab’s work to date has focused on leukemia and bone marrow transplantation, and previously, he worked as a research specialist in Dr. Carl June's laboratory, investigating cancer immunotherapy and CAR-T cell treatments.
More recently Dr. Schwab's research is centered on studying novel CAR-T cell therapy applications for addressing inflammation and atherosclerosis related to malignancies. In 2019, he founded Cartio Therapeutics, a biotech startup dedicated to developing cellular immunotherapy for cardiovascular disease.
Dr. Schwab received his Doctor of Medicine (M.D.) and Master of Science - MS, Translational Research, from the University of Pennsylvania and Bachelor of Arts (B.A.), Biophysics and Biochemistry from Amherst.
#RobertSchwab #PennMedicine #UniversityOfPennsylvaniaHealthSystem #CART #CarlJune #CancerImmunotherapy #CardiovascularDisease #AtheroscleroticPlaques #Atherosclerosis #Macrophages #OxidizedLDL #FoamCells #CARTregs #ChimericAntigenReceptor #TRegulatoryCells #ClonalHematopoiesisOfIndeterminatePotential #CVD #CheckpointInhibitors #Autoimmune #Cancer #Oncology #HematologyOncology #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #ResearchSupport the show
-
Send us a text
Dr. Frank Bedu-Addo, Ph.D. has served as a director, president and CEO of PDS Biotech ( https://pdsbiotech.com/ ) since its inception in 2005, a biotech company focused on transforming how the immune system targets and fights disease by developing a new generation of targeted cancer treatments.
Dr. Bedu-Addo is a veteran biotech executive with experience successfully starting and growing biotechnology organizations. He has been responsible for the development and implementation of both operational and drug development strategies, supervising and managing both large organizations and emerging biotechnology companies.
Dr. Bedu-Addo was a founding and senior executive at KBI BioPharma, Inc. As Vice President of Drug Development, he oversaw all business and drug development operations. Before his tenure at KBI, he successfully started and managed Cardinal Health’s East Coast biotechnology drug development operations.
Prior to Cardinal Health, Dr. Bedu-Addo was an Associate Director at Akzo-Nobel, Senior Scientist at Elan (The Liposome Co.), and Principal Scientist at Schering-Plough. In these positions, he contributed to the development of numerous drugs, including antiviral and anticancer products.
Dr. Bedu-Addo obtained his M.S. in Chemical Engineering and Ph.D. in Pharmaceutics from the University of Pittsburgh.
#FrankBeduAddo #PDSBiotech #ChemicalEngineering #Pharmaceutics #Liposomes #EnantiospecificCationicLipidNanoparticles #Versamune #IL12 #AntibodyDrugConjugate #HumanPapillomavirus #HPV #HeadAndNeckCancer #UniversalFluVaccines #TumorAssociatedProteins #Oncology #ProgressionFreeSurvival #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
-
Send us a text
Daniel Schmitt is President & Chief Executive Officer of Actuate Therapeutics, Inc. ( https://actuatetherapeutics.com/ ), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β).
Mr. Schmitt brings over 30 years of successful industry experience in operations management, new product development, and business development, having held senior executive positions in both large pharmaceutical and small biotechnology companies, including Fujisawa, Searle / Pharmacia, and Ilex Oncology. During his career, Daniel has led and contributed to the successful development and launch of multiple pharmaceutical products, and has constructed and executed numerous high value licensing, acquisition, and development deals for biotech and pharmaceutical companies, totaling nearly $1 billion in upfront and potential milestone payments.
Mr. Schmitt received his M.B.A and a B.S. in Chemistry from West Virginia University, and has held research positions affiliated with the National Foundation for Cancer Research and at the University of North Carolina School of Medicine. He has served as an Entrepreneur-in-Residence at Northwestern University, and as an external expert consultant for the University of Chicago and the University of Illinois-Chicago. Mr. Schmitt is also a founding member of Chicago Innovation Mentors.
#ActuateTherapeutics #GlycogenSynthaseKinase3Beta #GSK3β #Oncology #Cancer #Elraglusib #PancreaticDuctalAdenocarcinoma #PDAC #EwingSarcoma #Melanoma #ProgressionFreeSurvival #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
-
Send us a text
Fiona Cauley ( https://www.fionacauley.com ) is a Nashville-based comedy superstar who uses her comedy for a greater purpose – to raise awareness about her rare, genetic disease, Friedreich's Ataxia (FA), that progressively damages the nervous system, causing loss of muscle control over time, and is found in approximately one in 50,000 people worldwide (5,000 individuals in the United States and 15,000 worldwide).
Diagnosed at just 18 with this degenerative neurological condition, Fiona transformed adversity not just into an amazing career in comedy, but also beyond the stage, as an extremely powerful voice for disability visibility—sharing her story in conversations on podcasts and shows, and using comedy to foster understanding and empathy.
Fiona’s style has been defined as both fearless and impactful. She tackles everything from dating while in a wheelchair, to confronting audience discomfort and all sorts of stigma head-on.
Dr. David Lynch, MD, PhD, ( https://www.research.chop.edu/people/david-r-lynch ) is an attending neurologist in the Division of Neurology at Children's Hospital of Philadelphia (CHOP) and Director of the Friedreich's Ataxia Program ( https://www.chop.edu/centers-programs/friedreichs-ataxia-program ).
Dr. Lynch maintains a dynamic program focused on the Friedreich's Ataxia, which spans clinical, translational, and basic science research efforts on FA that include conducting double-blind clinical trials, identifying biomarkers, and leading mechanistic studies in animal and cellular models of FA.
The research conducted by Dr. Lynch and his lab team have led to a greater understanding of the metabolic dysfunction underlying FA. Their work has led to the creation of a patient database as well as a pipeline of more than 20 drug candidates that represent potential new therapies. Dr. Lynch is currently working with pharmaceutical industry partners to develop drug candidates as well as biomarkers for FA.
Dr. Lynch has a Medical Degree, and a Ph.D. in Neuroscience, from Johns Hopkins University School of Medicine, Baltimore.
Important Episode Links -
SKYCLARYS (omaveloxolone) - Patient Site - https://www.skyclarys.com/
"Friedreich's Back" - https://adage.com/video/viatris-friedreichs-back-6m38s/
#FionaCauley #FriedreichsAtaxia #RareDisease #Comedy #Comedian #DavidLynch #ChildrensHospitalOfPhiladelphia #Neurology #Biogen #Omaveloxolone #CannesLions #Humor #Laughter #Skyclarys #NikkiGlaser #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
-
Send us a text
Sarah Mastrorocco is Vice President and General Manager of Health at Instacart ( https://www.instacart.com/company/health ), the leading grocery technology company in North America, partnering with more than 1,800 retailers, covering nearly 100,000 stores, and serving over 7,000 consumer packaged goods brands.
An innovative leader with extensive expertise in business development and strategy, Sarah spearheaded the creation of Instacart Health and continues to oversee the initiative designed to support consumers, businesses, and nonprofits across three key areas: increasing nutrition security, inspiring healthier choices, and scaling food and nutrition programs within healthcare. In her role, she is focused on expanding consumer health tools and empowering organizations with technology to help improve access to nutritious food and nutrition education.
A longtime Instacart veteran, Sarah has played an integral role at the company since joining as the first member of the company’s business development team in 2014. During her tenure, she has held various leadership positions across business development and operations including building relationships with North America’s largest retailers, leading Instacart’s catalog, developing strategic partnerships, and scaling new businesses.
Previous to Instacart, Sarah held roles in other CPG companies, including at PepsiCo, in strategy, business innovation, and mergers and acquisitions, as well as at Hershey’s and in the consulting segment.
Sarah has an MBA from Northwestern University - Kellogg School of Management and a BS from the McIntire School of Commerce, at University of Virginia.
#SarahMastrorocco #Instacart #Health #NutritionSecurity #FoodDesert #SupplementalNutritionAssistanceProgram #MaternalHealth #MaternalOutcomes #FoodAsMedicine #HealthyLabel #Access #SocialDeterminantsOfHealth #HealthOutcomes
#ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
-
Send us a text
Dr. Forrest Ringold, MD of Surgical Association of Mobile ( https://sampadocs.com/about-us/dr-forrest-ringold/ ), is a leading expert in bariatric and robotic surgery and is renowned for his expertise in transforming lives through weight loss surgery and innovative abdominal treatments.
With an advanced understanding of both traditional laparoscopic techniques and cutting-edge robotic technology, Dr. Ringold specializes in a wide range of surgical procedures aimed at improving the health and quality of life of his patients, including life-changing weight loss surgeries such as sleeve gastrectomy, gastric bypass, duodenal switch, SADI, and lap band, as well as pioneering advancements in reflux surgery and esophageal and stomach diseases.
As a leading authority in his field, Dr. Ringold serves as a key opinion leader for both Intuitive Surgical and Teleflex Medical ( https://www.teleflex.com/usa/en/index.html ), two of the most respected names in medical devices. His innovative approach extends to the latest in gastrointestinal surgery, where he is actively pursuing groundbreaking advancements in magnetic anastomotic technology.
Dr. Ringold’s commitment to excellence extends beyond patient care. He is a clinical instructor at the University of South Alabama’s Department of Surgery, where he shares his wealth of knowledge with the next generation of surgeons. His dedication to his craft is also reflected in his leadership roles, including his current position as President of the Alabama State Chapter of the American Society for Metabolic and Bariatric Surgery.
Since 2018, Dr. Ringold has led the Epicenter at Mobile Infirmary Medical Center, a distinguished program designed to train surgeons nationwide in the fields of robotic and bariatric surgery.
Dr. Ringold attended medical school at University of South Alabama Medical School and did his residency in general surgery at University of South Alabama Medical Center.
#ForrestRingold #SurgicalAssociationOfMobile #Bariatric #RoboticSurgery #WeightLossSurgery #SleeveGastrectomy #GastricBypass #DuodenalSwitch #LapBand #MagneticAnastomoticTechnology #TeleflexMedical #SouthAlabamaMedicalSchool #ObesitySurgery #PostoperativeReflux #DeNovoGastroesophagealRefluxDisease #GERD #TitanSGSStapler #SurgicalStaplers #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
-
Send us a text
Aarti Holla-Maini is Director of the United Nations Office for Outer Space Affairs ( UNOOSA - https://www.unoosa.org/oosa/de/aboutus/director.html ) in Vienna, part of the UN organization ( https://www.un.org/ ) that works to promote international cooperation in the peaceful use and exploration of space, and in the utilization of space science and technology for sustainable economic and social development.
Ms. Holla-Maini brings to this position over 25 years of professional experience in the space sector including in managerial and advocacy functions. Most recently, she has held the role of Executive Vice-President Sustainability, Policy & Impact at NorthStar Earth & Space; prior to which she spent over 18 years as Secretary-General of the Global Satellite Operators Association.
Ms. Holla-Maini’s experience includes service as a member of the World Economic Forum's Global Future Council on Space; member of the Advisory Group of the Space Sustainability Rating managed by eSpace at the École Polytechnique Fédérale de Lausanne (EPFL) Space Center; member of the Advisory Board of the Satellite Industry Association of India; Senior Space Policy Adviser to Forum Europe and as Expert Adviser on Space Traffic Management for European Union studies 2021-2023. She was also one of the chief architects of the Crisis Connectivity Charter established in 2015 for emergency telecommunications via satellite with the UN World Food Program’s Emergency Telecommunications Cluster.
Ms. Holla-Maini holds a bachelor’s degree in law with German law from Kings College London, UK, a master’s degree in business administration from HEC Paris, France, and she is also an alumna of the International Space University.
#AartiHollaMaini #UnitedNationsOfficeForOuterSpaceAffairs #UN #Airbus #GlobalSatelliteOperatorsAssociation #UNOOSA #SpaceObjectRegister #SpaceLaw #SustainableDevelopmentGoals #SDG #CommitteeOnThePeacefulUsesOfOuterSpace #COPUOS #PlanetaryDefense #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcastSupport the show
-
Send us a text
Dr. Sunita Satyapal, Ph.D. is an internationally known subject matter expert and leader in the field of hydrogen and fuel cells with three decades of experience in government, industry, and academia.
Dr. Satyapal has had diverse roles including as a researcher, a visiting assistant professor, as Chief Engineer and Director for the U.S. Department of Energy’s Hydrogen and Fuel Cell Technologies Office ( https://www.energy.gov/eere/person/sunita-satyapal ), and as a manager in industry at United Technologies, overseeing research and development (R&D) as well as business development and stakeholder collaboration. She has been responsible for R&D in industry as well as developing national hydrogen strategies, coordinating over $10 billion in hydrogen funding over the years, and collaborating across more than 25 countries through global hydrogen partnerships.
Dr. Satyapal received her Ph.D. from Columbia University and completed postdoctoral work in Applied and Engineering Physics at Cornell University. She has also served in business development, management, and deployment related roles in industry. She has numerous publications, including in Scientific American, 10 patents, and various recognitions including a Meritorious and a Distinguished Presidential Rank Award.
#Hydrogen #FuelCell #SunitaSatyapal #DepartmentOfEnergy #PhysicalChemistry #Photodissociation #Electrolysis #EnergySecurity #GreenhouseGasEmissions #RenewableEnergy #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
-
Send us a text
Colonel Dr. Tanja Roy is Commander, U.S. Army Medical Research Institute of Chemical Defense ( https://usamricd.health.mil/ ), a subsidiary of United States Army Medical Research and Materiel Command (USAMRMC) and is the leading science and technology laboratory of the Department of Defense for the development, testing, and evaluation of medical chemical warfare countermeasures, including therapies and materials to treat casualties of chemical warfare agents, as well as biochemical and other emerging non-kinetic acute battlefield injuries.
Colonel Dr. Roy received her commission from the University of Notre Dame Reserve Officer Training Corps as a Distinguished Military Graduate in 2000 into the Army Medical Specialist Corps.
Colonel Dr. Roy holds a Doctor of Philosophy degree from the University of Pittsburgh (Rehabilitation Sciences/Epidemiology), Doctor and Master of Physical Therapy from Baylor University, Master of Science from the University of Pittsburgh (Epidemiology), and Master of Strategic Studies from the U.S. Army War College.
Colonel Dr. Roy recently served as the Director of Occupational Health Sciences at the Defense Centers for Public Health.
Previously, Colonel Dr. Roy created and served as Director of the Soldier Performance, Health, and Readiness Database at the U.S. Army Research Institute of Environmental Medicine (USARIEM). Previous assignments include executive officer for the Clinical Public Health and Epidemiology Directorate, Army Public Health Center; Physical Therapy Researcher, University of Pittsburgh; Physical Therapy Researcher at USARIEM; Chief, Physical Therapy Troop Medical Clinic, Fort Drum; Chief, Physical Therapy, 3rd Infantry Brigade Combat Team, Fort Drum and Afghanistan; Assistant Chief, Baumholder Physical Therapy Clinic; Chief, Physical Therapy, 701st Main Support Battalion, 1st Infantry Division, Iraq; Physical Therapist, 31st Combat Support Hospital, Iraq; Chief, Baumholder Physical Therapy Clinic; and Physical Therapist, Landstuhl Regional Medical Center. She has 29 medical research publications.
Colonel Dr. Roy is a graduate of the U.S. Army Medical Department (AMEDD) Officer Basic Course, the AMEDD Captains Career Course, Intermediate Level Education, the Defense Strategy Course, and U.S. Army War College. She is Airborne Qualified (5P); a Strategic Studies Graduate (6Z); an Army Medical Department Acquisitions Officer (8X); a certified Medical Research, Development, Testing, and Evaluation Officer (8Z); and holds the Medical Proficiency Designator (9A).
Colonel Dr. Roy’s awards and decorations include the Meritorious Service Medal (4 oakleaf clusters), Army Commendation Medal (2 oakleaf clusters), Army Achievement Medal, Afghanistan Campaign Medal, Global War on Terrorism Expeditionary Medal and Soldier Medal, Military Outstanding Volunteer Medal, Humanitarian Service Medal, Overseas Service Medal (1 oakleaf cluster), Joint Meritorious Unit Award, Army Superior Unit Award (3 oakleaf clusters), Meritorious Unit Award (1 oakleaf cluster), Parachutist Badge, German Sports Badge (Gold), and Combat Medic Badge. She is a member of the Order of Military Medical Merit.
#TanjaRoy #USArmyMedicalResearchInstituteOfChemicalDefense #BattlefieldInjuries #ClinicalTraining #MedicalResearch #Warfighter #MedicalCountermeasures #NerveAgents #Vesicants #SulfurMustard #MetabolicPoisons #Cyanide #PulmonaryToxicants #Phosgene #MRICD #DepartmentOfDefense #AberdeenProvingGround #Toxin #Toxicant #PharmaceuticalSciences #ChemicalWarfare #CBRN #Epidemiology #PhysicalTherapy #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
-
Send us a text
Paurvi Bhatt is the Interim CEO of the Rosalynn Carter Institute for Caregivers ( https://rosalynncarter.org/ ), an organization that drives transformative systems change to improve the strength, health, and resilience of family caregivers.
Paurvi is also the Founder and CEO of ThirdEyeFocus, a consultancy for private companies & nonprofits focused on the care economy.
Paurvi is a global healthcare executive known for creating strategies that optimize public, private, and philanthropic capital to expand more equitable decisions, resources, and care outcomes in communities around the world. She’s known for creating unique solutions that bring together nonprofits, government and companies to pilot, pivot, and scale health care and social services.
As a second generation, Indian immigrant, and family caregiver, Paurvi focuses on culturally responsive solutions in the care economy by integrating community-led voices, solutions, and organizations to shape the referral pathway that brings care into the home.
As a board director, leader and advisor on several private company, foundation, institution and nonprofit boards, Paurvi combines her lived experience with her seasoned focus on outcomes and deep knowledge of financing.
Paurvi has focused much of her career on HIV/AIDS; women’s health and health equity worldwide and is trained in health systems and economics with a B.A. in Neuroscience from Northwestern University, an M.P.H from Yale University (Health Management and Population Economics), and a PhD (ABD - Global Health Systems and Economics) from Johns Hopkins University.
Paurvi is an active spokesperson, author, podcast guest and presenter on issues ranging from women’s leadership, Asian American and immigrant issues, health systems and economics, philanthropy, HIV and women’s health, and the role of women as working daughters and family caregivers.
#PaurviBhatt #TheRosalynnCarterInstituteForCaregivers #Caregivers #CareEconomy #Caregiving #Dementia #Cancer #CorporateSocialResponsibility #Philanthropy #WomensHealth #HIV #AIDS #MedtronicFoundation #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
-
Send us a text
Dr. Mark Jacobs is the Director of Pacific Technical Support and WHO Representative to the South Pacific. He was appointed in this position in August 2021. Prior to this, he has held a series of senior public health leadership roles.
Dr. Jacobs was previously the WHO Representative to Lao People’s Democratic Republic from November 2018 to August 2021. From May to October 2018, Dr Jacobs was Acting Director of Programme Management for WHO in the Western Pacific Region. He was also previously the Director of Communicable Diseases in the Region for 5 years.
Before joining WHO, Dr. Jacobs was New Zealand’s Director of Public Health for 9 years and managed the Public Health Programme at the Secretariat of the Pacific Community for 3 years. He also spent several years in Director of Public Health roles for state health authorities in Australia.
Dr. Jacobs’ interests include developing healthy public policy, strengthening disease surveillance, strengthening all hazards emergency preparedness, and working across sectors to improve health.
Dr. Jacobs holds a Bachelor of Medicine, Bachelor of Surgery, a Graduate Diploma in Health Services Management and a Master of Public Health.
#MarkJacobs #WHO #WorldHealthOrganization #SouthPacific #CommunicableDiseases #PublicHealth #DiseaseSurveillance #AllHazardsEmergencyPreparedness #InfectiousDisease #Fiji #NoncommunicableDiseases #WesternPacificRegion #HealthSecurity #AntimicrobialResistance #OneHealth #Aging #Ageing #Healthspan #Anxiety #Loneliness #Depression #ClimateChange #AirPollution #EnvironmentalHazards #PacificIslands #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
-
Send us a text
Dr. Sui Huang, MD, PhD is a Professor at the Institute for Systems Biology ( ISB - https://isbscience.org/people/sui-huang-md-phd/?tab=biography ) where his lab is focused on studying how gene regulatory networks control gene activity to create stable cellular states, such as different cell types, and how these states transition into different lineages in both healthy and diseased conditions.
Dr. Huang is a molecular and cell biologist with a strong background in theoretical biology and has devoted much of his research to understanding the very phenomenon of cancer from a complex systems perspective.
Before joining the ISB in fall 2011, Dr. Huang held faculty positions at the University of Calgary (Institute of Biocomplexity and Informatics), where he helped establish biocomplexity as a discipline in research and teaching, and at Harvard Medical School (Children’s Hospital) where he obtained first experimental evidence for the existence of high-dimensional attractors in mammalian gene regulatory networks.
Dr. Huang grew up in Geneva and Zurich. He received his MD degree from the University of Zurich and obtained thereafter, as the first recipient of the PhD-Program-for-Physicians Award of the Swiss National Science Foundation, his PhD in molecular biology and physical chemistry for work on interferons. As a postdoctoral fellow at Children’s Hospital Boston he investigated tumor angiogenesis and cell growth control. In that period he also studied dynamical systems through his affiliation with the New England Complex Systems Institute.
Important Episode Link - "The end of the genetic paradigm of cancer" - PLOS Biology
https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003052
#SuiHuang #InstituteForSystemsBiology #Interferon #Angiogenesis #AttractorStates #Epigenetics #Cancer #Oncology #TumorMicroenvironment #DonaldIngber #ConradWaddington #Organogenesis #Morphogenesis #LeeHood #BeatriceMintz #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #ResearchSupport the show
-
Send us a text
Dr. Samir Khleif, MD is CEO of Georgiamune ( https://www.georgiamune.com/team ), a private, science and discovery clinical stage immunotherapeutic biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases.
Dr. Khleif is a pioneer in the field of immunotherapy. He is a medical oncologist, immunologist, innovator, and entrepreneur, as well as a transformational executive in health care and biomedical research.
Prior to becoming CEO of Georgiamune, Dr. Khleif served in different academic and leadership positions. He was a National Cancer Institute (NCI)/National Institutes of Health (NIH) scientist and Chief of the NCI Cancer Vaccine Section, where he led the development of pioneering immune-oncology and cancer vaccines into clinical trials. As a national and international academic leader, and detailed by the US government, he served as the founding director and CEO of the King Hussein Cancer Center ( https://www.khcc.jo/en ) in Amman, Jordan, where he led the development of the largest cancer center in the MENA region. He also served as the director of the Georgia Cancer Center, the state cancer center, at Augusta University. He is currently a biomedical scholar and holds a professorship at Georgetown University Medical School.
Dr. Khleif also served as a Special Assistant to the Commissioner of the FDA, leading the FDA's Critical Path Initiative for Oncology. He is a member of the board of directors of Ayala Pharmaceuticals and Emerald Biopharmaceutics, and served as a member of the scientific advisory board of more than 20 biotechnology and pharmaceutical companies.
Dr. Khleif is an international KOL in immunology and immunotherapy. He has served on many national committees, including the Scientific Advisory Board of the Biden Cancer Initiative, as chair of the Immunotherapy Committee for NRG, and as a member of the NCI Cooperative Group. He currently serves as an advisor for the Parker Institute for Cancer Immunotherapy.
Dr. Khleif is an editor of three books, the author of hundreds of peer-reviewed scientific research articles, and a prolific inventor with more than 150 patents issued or pending in the field of immunology and immunotherapy.
Dr. Khleif received his medical degree at the University of Jordan, Amman Jordan. He completed his residency in Internal Medicine at the Medical College of Ohio and his fellowship in Medical Oncology at the National Cancer Institute (NCI) in Bethesda, Maryland.
#SamirKhleif #Georgiamune #Immunotherapy #KingHusseinCancerCenter #CriticalPathInitiative #FDA #Tregs #RegulatoryTCells #Cancer #Oncology #CheckpointInhibitors #ImmuneEscapeMechanisms #DualFunctioningAntibody #Autoimmune #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #ResearchSupport the show
- Visa fler
